Civitas Networks for Health Welcomes 11 New Members During First Half of 2023
Organization Seeing Continuous Membership Growth and Interest Year-Over-YearWASHINGTON, July 10, 2023 (GLOBE NEWSWIRE) -- Civitas Networks for Health today announced...
Year: 2023
Brain Power Wellness Reviews Latest Annual BPW Staff Retreat
Brain Power Wellness, a holistic, school-based wellness organization, reviews its latest staff retreat, which was held June 20-22, 2023. Brain...
Cheek Week Kicks Off July 10 in Support of African American Bone Marrow Awareness Month
Be The Match® makes appeal for more blood stem cell and marrow donorsATLANTA, July 10, 2023 (GLOBE NEWSWIRE) -- Did...
Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.LOS ANGELES, July 10, 2023 (GLOBE...
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.LOS ANGELES, July 10, 2023 (GLOBE...
Be The Match BioTherapies® Marks Cord Blood Awareness Month with the Announcement of the Cord Blood Bank Alliance
The Be The Match BioTherapies Cord Blood Bank Alliance will work to grow the use of cord blood as a...
Route 92 Medical Announces Appointment of Chris Hartman as Chief Commercial Officer
Chris Hartman Chris Hartman, Chief Commercial Officer, Route 92 MedicalSAN MATEO, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Route 92...
Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test
Registration with the NMPA, China’s Regulatory Equivalent to the FDA, is a Prerequisite to Marketing and Distribution BEIJING, July 10,...
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of...
Jupiter Wellness Acquires World’s First Rapid Blood Alcohol Detox Drink “Safety Shot” to Launch Q4 2023: Lowers Blood Alcohol Content by up to 50% in Just 30 Minutes
Jupiter Wellness, Inc World’s First Rapid Blood Alcohol Detox Drink “Safety Shot”Asset valued at $53 million by a third party...
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on...
Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
SOLANA BEACH, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...
Teladoc Health to Announce Second Quarter 2023 Financial Results
PURCHASE, NY, July 10, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care,...
Cerevance Announces Presentation at the Alzheimer’s Association International Conference
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation...
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in...
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of studyBOSTON and...
NKGen Announces Poster Presentation at the 2023 Alzheimer’s Association International Conference
SANTA ANA, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the...